Drug Industry Faces Vast Antitrust Probe
As part of a wide probe into anticompetitive practices in the prescription drug industry, the Federal Trade Commission will subpoena nearly 200 pharmaceutical companies to determine whether they are stifling competition...To view the full article, register now.
Already a subscriber? Click here to view full article